from 10-K 4 pages As of the Filing Date of Our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023, Our Authorized Capital Stock Consists of 3,205,000,000 Shares, of Which 3,200,000,000 Shares Are Common Stock, Without Par Value, and 5,000,000 Shares Are Preferred Stock, Without Par Value. No Shares of Preferred Stock Are Issued and Outstanding as of the Filing Date of Our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023. Common Stock Dividend Rights. Subject to the Dividend Rights of the Holders of Any Outstanding Shares of Preferred Stock, the Holders of Shares of Common Stock Are Entitled to Receive Ratably Dividends as May Be Lawfully Declared at Any Time by Our Board of Directors

from 10-K 15 pages Eli Lilly and Company Shareholder Value Award Agreement

from 10-K 15 pages Eli Lilly and Company Relative Value Award Agreement

from 10-K 16 pages Eli Lilly and Company Restricted Stock Unit Award Agreement

from 10-K 13 pages Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees as Amended Effective January 1, 2024

from 10-K 4 pages Subsidiaries of the registrant

from 10-K 1 page Consent of expert or counsel

from 10-K 1 page Management certification of annual or quarterly disclosure

from 10-K 1 page Management certification of annual or quarterly disclosure

from 10-K 1 page Management certification of financial report

from 10-K 7 pages  

from 10-K lly-20231231_g1.jpg